CN1891296A - 含有钙拮抗剂和苯氧酸类化合物的药物组合物 - Google Patents
含有钙拮抗剂和苯氧酸类化合物的药物组合物 Download PDFInfo
- Publication number
- CN1891296A CN1891296A CNA2005100816716A CN200510081671A CN1891296A CN 1891296 A CN1891296 A CN 1891296A CN A2005100816716 A CNA2005100816716 A CN A2005100816716A CN 200510081671 A CN200510081671 A CN 200510081671A CN 1891296 A CN1891296 A CN 1891296A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- rat
- application
- fenofibrate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims description 16
- 239000002253 acid Substances 0.000 title abstract 2
- 239000000801 calcium channel stimulating agent Substances 0.000 title 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 34
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 23
- 239000000480 calcium channel blocker Substances 0.000 claims abstract description 22
- 230000008816 organ damage Effects 0.000 claims abstract description 12
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 7
- 206010020772 Hypertension Diseases 0.000 claims description 85
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 85
- 229960002297 fenofibrate Drugs 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 45
- 229960003580 felodipine Drugs 0.000 claims description 43
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 42
- 229960000528 amlodipine Drugs 0.000 claims description 42
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 38
- 229960005425 nitrendipine Drugs 0.000 claims description 36
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 35
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 34
- YWQGBCXVCXMSLJ-UHFFFAOYSA-N beclobrate Chemical compound C1=CC(OC(C)(CC)C(=O)OCC)=CC=C1CC1=CC=C(Cl)C=C1 YWQGBCXVCXMSLJ-UHFFFAOYSA-N 0.000 claims description 34
- 229960002174 ciprofibrate Drugs 0.000 claims description 34
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims description 33
- 229950009252 beclobrate Drugs 0.000 claims description 33
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 33
- 229960004569 indapamide Drugs 0.000 claims description 31
- 229950004646 azelnidipine Drugs 0.000 claims description 29
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 29
- 229960004340 lacidipine Drugs 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 25
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 24
- 229960000516 bezafibrate Drugs 0.000 claims description 23
- 239000003826 tablet Substances 0.000 claims description 20
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 18
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 17
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 229960003627 gemfibrozil Drugs 0.000 claims description 15
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 12
- -1 fibric acid compound Chemical class 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 11
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 claims description 9
- 229950008554 levamlodipine Drugs 0.000 claims description 9
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 8
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 8
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 8
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 8
- 229960004166 diltiazem Drugs 0.000 claims description 8
- 230000001077 hypotensive effect Effects 0.000 claims description 8
- 229960004427 isradipine Drugs 0.000 claims description 8
- 229960001783 nicardipine Drugs 0.000 claims description 8
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 8
- 229960001597 nifedipine Drugs 0.000 claims description 8
- 229960001722 verapamil Drugs 0.000 claims description 8
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000227 nisoldipine Drugs 0.000 claims description 7
- QDGIAPPCJRFVEK-UHFFFAOYSA-N (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate Chemical compound C1CN(C)CCC1OC(=O)C(OC=1C=CC(Cl)=CC=1)OC1=CC=C(Cl)C=C1 QDGIAPPCJRFVEK-UHFFFAOYSA-N 0.000 claims description 6
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 6
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims description 6
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims description 6
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 claims description 6
- 229960002992 barnidipine Drugs 0.000 claims description 6
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 229960003020 cilnidipine Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229960003501 etofibrate Drugs 0.000 claims description 6
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 claims description 6
- 229950009036 etofylline clofibrate Drugs 0.000 claims description 6
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 claims description 6
- 229950009619 lifibrate Drugs 0.000 claims description 6
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 claims description 6
- 229950000109 niludipine Drugs 0.000 claims description 6
- 229960005366 nilvadipine Drugs 0.000 claims description 6
- 229960000715 nimodipine Drugs 0.000 claims description 6
- 229960004058 simfibrate Drugs 0.000 claims description 6
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 claims description 5
- BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 claims description 5
- 229950004495 binifibrate Drugs 0.000 claims description 5
- NRWBCTIORMNETF-CZIZESTLSA-N chembl2107166 Chemical compound C1=C(Cl)C(S(=O)(=O)N(C)C)=CC(C=2N(C(=N\C=3C=CC=CC=3)/SC=2)C)=C1 NRWBCTIORMNETF-CZIZESTLSA-N 0.000 claims description 5
- 229950003072 clinofibrate Drugs 0.000 claims description 5
- 229960001214 clofibrate Drugs 0.000 claims description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229950010921 metibride Drugs 0.000 claims description 5
- 229960000804 ronifibrate Drugs 0.000 claims description 5
- AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical compound C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 201000009925 nephrosclerosis Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 235000015170 shellfish Nutrition 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 210000000709 aorta Anatomy 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000002224 dissection Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000000505 pernicious effect Effects 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940060038 chlorine Drugs 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 abstract description 50
- 150000002632 lipids Chemical class 0.000 abstract description 30
- 230000002792 vascular Effects 0.000 abstract description 8
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 4
- 241000700159 Rattus Species 0.000 description 155
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 62
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 50
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 47
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 36
- 201000005577 familial hyperlipidemia Diseases 0.000 description 32
- 102000002045 Endothelin Human genes 0.000 description 31
- 108050009340 Endothelin Proteins 0.000 description 31
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 30
- 210000002700 urine Anatomy 0.000 description 30
- 230000035487 diastolic blood pressure Effects 0.000 description 28
- 229920002472 Starch Polymers 0.000 description 27
- 235000019698 starch Nutrition 0.000 description 27
- 239000008107 starch Substances 0.000 description 27
- 230000029142 excretion Effects 0.000 description 25
- 230000001631 hypertensive effect Effects 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 24
- 230000035488 systolic blood pressure Effects 0.000 description 22
- 235000013305 food Nutrition 0.000 description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 18
- 235000019359 magnesium stearate Nutrition 0.000 description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 18
- 239000008108 microcrystalline cellulose Substances 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 8
- 229960004005 amlodipine besylate Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000007779 soft material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 241000282894 Sus scrofa domesticus Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000010241 blood sampling Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000021590 normal diet Nutrition 0.000 description 7
- 229960002662 propylthiouracil Drugs 0.000 description 7
- 210000002254 renal artery Anatomy 0.000 description 7
- 230000000630 rising effect Effects 0.000 description 7
- 229910052709 silver Inorganic materials 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 229960001770 atorvastatin calcium Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011265 semifinished product Substances 0.000 description 4
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 3
- 229940022418 caduet Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 收缩压(mmHg) | 舒张压(mmHg) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型氨氯地平非诺贝特氨氯地平+非诺贝特 | --0.5300.5+30 | 100.2±9.8169.4±24.4##172.5±26.7173.2±20.9168.9±30.6 | 96.4±10.1175.8±29.4##145.2±21.6**166.5±20.5140.8±26.6** | 65.6±5.9133.3±22.1##134.8±20.6132.9±16.9135.4±20.9 | 63.1±6.7140.2±24.3##96.4±14.0**125.6±13.482.2±13.3**▲ |
组别 | 剂量(mg/kg) | TG(mmol/L) | VLDL(mmol/L) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型氨氯地平非诺贝特氨氯地平+非诺贝特 | --0.5300.5+30 | 0.62±0.102.14±0.32##2.05±0.211.95±0.312.03±0.53 | 0.77±0.092.10±0.30##1.85±0.401.42±0.30**1.14±0.20**▲ | 0.16±0.030.44±0.10##0.42±0.090.41±0.080.43±0.07 | 0.13±0.050.45±0.10##0.41±0.090.27±0.08**0.20±0.04**▲ |
组别 | 剂量(mg/kg) | 24h尿微量白蛋白(μg) | NO(μmol/L) | ET(pg/ml) |
正常对照模型氨氯地平非诺贝特氨氯地平+非诺贝特 | --0.5300.5+30 | 17.9±6.577.8±21.4##54.3±14.2**75.2±25.240.5±14.8**▲ | 33.4±10.622.5±6.7##24.6±7.328.6±6.1*35.3±6.8**▲ | 67.5±16.4145.2±33.8##133.9±28.7103.5±30.1**86.3±24.1** |
组别 | 剂量(mg/kg) | 收缩压(mmHg) | 舒张压(mmHg) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型尼群地平环丙贝特尼群地平+环丙贝特 | --1.02.01.0+2.0 | 112.4±13.7170.3±30.2##171.9±23.5168.5±31.2167.8±23.8 | 107.3±12.6167.3±25.2##133.7±16.4**157.6±23.5120.8±14.9** | 70.6±8.3133.5±18.5##130.3±14.2129.4±12.1128.9±10.6 | 74.4±7.4135.1±14.3##96.6±12.9**125.5±16.184.3±11.9**▲ |
组别 | 剂量(mg/kg) | TG(mmol/L) | VLDL(mmol/L) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型尼群地平环丙贝特尼群地平+环丙贝特 | --1.02.01.0+2.0 | 0.50±0.102.04±0.32##1.92±0.271.96±0.301.95±0.28 | 0.53±0.091.96±0.26##1.83±0.311.41±0.23**1.13±0.21**▲ | 0.20±0.060.53±0.08##0.54±0.010.52±0.070.55±0.10 | 0.18±0.040.60±0.10##0.50±0.050.38±0.13**0.24±0.11**▲ |
组别 | 剂量(mg/kg) | 24h尿微量白蛋白(μg) | NO(μmol/L) | ET(pg/ml) |
正常对照模型尼群地平环丙贝特尼群地平+环丙贝特 | --1.02.01.0+2.0 | 46.8±16.6138.9±43.6##88.4±25.2**114.7±28.863.1±16.3**▲ | 54.5±14.625.5±6.8##30.4±10.139.2±12.7**53.6±10.7**▲ | 45.8±13.287.4±24.3##74.6±30.165.2±20.3*57.6±14.6** |
组别 | 剂量(mg/kg) | 收缩压(mmHg) | 舒张压(mmHg) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型非洛地平苄氯贝特非洛地平+苄氯贝特 | --1.0101.0+10 | 90.1±10.2163.2±28.1##160.8±31.3163.5±34.2161.2±30.6 | 92.3±9.6170.1±32.1##130.1±22.4**151.7±26.5120.2±20.4** | 60.5±7.4114.1±16.4##116.2±20.3113.3±18.9116.3±13.8 | 64.3±5.5110.7±14.2##85.9±9.7**105.4±13.876.5±10.2**▲ |
组别 | 剂量(mg/kg) | TG(mmol/L) | VLDL(mmol/L) | ||
给药前 | 给药8W后 | 给药前 | 给药8W后 | ||
正常对照模型非洛地平苄氯贝特非洛地平+苄氯贝特 | --1.0101.0+10 | 0.38±0.061.48±0.25##1.43±0.301.45±0.221.50±0.33 | 0.37±0.071.50±0.21##1.36±0.310.94±0.18**0.76±0.14**▲ | 0.12±0.040.40±0.03##0.39±0.060.38±0.080.37±0.07 | 0.14±0.030.42±0.07##0.35±0.060.29±0.05**0.22±0.03**▲ |
组别 | 剂量(mg/kg) | 24h尿微量白蛋白(μg) | NO(μmol/L) | ET(pg/ml) |
正常对照模型非洛地平苄氯贝特非洛地平+苄氯贝特 | --1.0101.0+10 | 21.4±6.269.6±21.6##48.2±13.6**63.4±14.332.1±16.5**▲ | 44.4±10.625.3±5.4##30.6±6.333.8±9.5*41.8±7.8** | 135.4±33.4249.6±41.8##234.2±50.6185.4±55.7**154.5±44.9**▲ |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100816716A CN1891296B (zh) | 2005-07-06 | 2005-07-06 | 含有钙拮抗剂和苯氧酸类化合物的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100816716A CN1891296B (zh) | 2005-07-06 | 2005-07-06 | 含有钙拮抗剂和苯氧酸类化合物的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1891296A true CN1891296A (zh) | 2007-01-10 |
CN1891296B CN1891296B (zh) | 2010-04-21 |
Family
ID=37596657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100816716A Active CN1891296B (zh) | 2005-07-06 | 2005-07-06 | 含有钙拮抗剂和苯氧酸类化合物的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1891296B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616651A (zh) * | 2020-05-08 | 2021-11-09 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
-
2005
- 2005-07-06 CN CN2005100816716A patent/CN1891296B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616651A (zh) * | 2020-05-08 | 2021-11-09 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
CN113616651B (zh) * | 2020-05-08 | 2023-12-29 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1891296B (zh) | 2010-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1117566C (zh) | 包含氨氯地平和抑制素化合物的联合药物形式 | |
CN1651087A (zh) | 有机化合物的联合形式 | |
CN1891229A (zh) | 预防或治疗代谢综合征的药物制剂 | |
CN1765362A (zh) | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 | |
CN1631247A (zh) | 一种耐缺氧抗疲劳的保健食品及其制备工艺 | |
CN1931143A (zh) | 口服控制释放的曲美他嗪药物组合物 | |
CN1205934C (zh) | 治疗高血脂症的组合物 | |
CN1682719A (zh) | 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法 | |
CN1527700A (zh) | 制备苯妥英钠剂型的压缩方法 | |
CN101057678A (zh) | 一种含有天然植物提取物或单体的组合物 | |
CN1269529C (zh) | 含有血管紧张素转化酶抑制剂和b族维生素的药物组合物 | |
CN1891296A (zh) | 含有钙拮抗剂和苯氧酸类化合物的药物组合物 | |
CN1194691C (zh) | 治疗高血脂症的组合物 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1499961A (zh) | 一种在胃液中漂浮并多脉冲释放活性物质的药用片剂系统、该系统和该系统包封物的制备方法 | |
CN1286844C (zh) | 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物 | |
CN1903364A (zh) | 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物 | |
CN1803144A (zh) | 含有氯贝丁酯类化合物和b族维生素的药物组合物 | |
CN1247198C (zh) | 治疗高血脂症的组合物 | |
CN1827169A (zh) | 含有硝酸酯类药物和HMG-CoA还原酶抑制剂的组合物制剂 | |
CN100350915C (zh) | 治疗代谢综合症的药物 | |
CN1827170A (zh) | 含有二氢吡啶类钙拮抗剂和苯氧芳酸类药物的组合物 | |
CN1631358A (zh) | 含有盐酸伪麻黄碱的治疗感冒的复方散剂及其处方和制备方法 | |
CN1709257A (zh) | 治疗高血脂症的组合物 | |
CN1692906A (zh) | 治疗高血脂症的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ANHUI BIOLOGICAL MEDICAL SCIENCE INST. Effective date: 20120713 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120713 Address after: 4103 box 230038, Anhui University of Traditional Chinese Medicine, Mount Mei Road, Shushan District, Anhui, Hefei Co-patentee after: Anhui Biological Medical Institute Patentee after: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER Address before: 4103 box 230038, Anhui University of Traditional Chinese Medicine, Mount Mei Road, Shushan District, Anhui, Hefei Patentee before: Anhui Modern Chinese Medicine Research Center |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition containing calcium agonist and phenoxy acid compound Effective date of registration: 20130529 Granted publication date: 20100421 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER|Anhui Biological Medical Institute Registration number: 2013990000325 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130606 Granted publication date: 20100421 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER|Anhui Biological Medical Institute Registration number: 2013130000002 Date of cancellation: 20130606 Granted publication date: 20100421 Pledgee: Lianyungang Shanhai Company limited by guarantee Pledgor: Zhang Wanpeng Registration number: 2013130000001 Date of cancellation: 20130606 Granted publication date: 20100421 Pledgee: Industrial and Commercial Bank of China Pledgor: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER|Anhui Biological Medical Institute Registration number: 2013320000006 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition containing calcium agonist and phenoxy acid compound Effective date of registration: 20130606 Granted publication date: 20100421 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER|Anhui Biological Medical Institute Registration number: 2013130000002 Denomination of invention: Medicinal composition containing calcium agonist and phenoxy acid compound Effective date of registration: 20130606 Granted publication date: 20100421 Pledgee: Lianyungang Shanhai Company limited by guarantee Pledgor: Zhang Wanpeng Registration number: 2013130000001 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20100421 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER|Anhui Biological Medical Institute Registration number: 2013990000325 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000325 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180507 Address after: 230032 mail box 92, Medical University Of Anhui, 81 Shushan Meishan Road, Shushan, Hefei. Patentee after: Anhui Biological Medical Institute Address before: 230038 mailshan Road, Anhui University of Traditional Chinese Medicine, Shushan, Anhui, 4103 PO box, Anhui University of Traditional Chinese Medicine Co-patentee before: Anhui Biological Medical Institute Patentee before: Anhui Modern Chinese Medicine Research Center |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230518 Address after: 518057, 1st and 2nd floors of Building 2, Phase III of the Biological Incubator, No. 16, Gaoxin Middle Road, High tech Zone, Nanshan District, Shenzhen City, Guangdong Province; East side of the first floor and 2nd and 3rd floors of Building 3 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anhui Biological Medical Institute Address before: 230032 mail box 92, Medical University Of Anhui, 81 Shushan Meishan Road, Shushan, Hefei. Patentee before: Anhui Biological Medical Institute |